Management of systemic lupus erythematosus (SLE)

Clinical and Experimental Allergy

Volumn 31, Issue 5, 2001, Pages 686-693

  Morton, S J ^a   Powell, R J ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; C REACTIVE PROTEIN; CELL NUCLEUS ANTIGEN; CHLORAMBUCIL; CLADRIBINE; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DNA ANTIBODY; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOPTERIN; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; TACROLIMUS; THALIDOMIDE; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; BONE MARROW TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOPENIA; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL SYMPTOM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHOTOCHEMOTHERAPY; PLASMAPHERESIS; PRIORITY JOURNAL; RETINOPATHY; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0034857410     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01123.x     Document Type: Conference Paper

References (71)

1. Antinuclear antibodies and disease specificity
2. Special article: The 1982 revised criteria for the classification of systemic lupus erythematosus
3. Oral contraceptives and systemic lupus erythematosus
4. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE)
5. Systemic corticosteroid therapy in systemic lupus erythematosus
6. Value of urinary neopterin in the differential diagnosis of bacterial and viral infections
7. Accelerated atherosclerosis and coronary disease in SLE
8. Antimalarial therapies
9. Editorial: Hydroxychloroquine: Past, present, future
10. Toxic effects of Chloroquine and Hydroxychloroquine (Table 60.5)
11. Hydroxychloroquine retinopathy: Is screening necessary?
12. Lupus eritimatoso fijo (su tratamiento con talidomida)
13. Thalidomide treatment of subacute cutaneous lupus erythematosus
14. Treatment of lupus erythematosus profundus with thalidomide
15. Treatment of cutaneous lesions of systemic lupus erythematosus with thalidomide
16. Guideline for the clinical use and dispensing of thalidomide
17. Neuropathy after intake of thalidomide (Distaval)
18. Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosus
19. Methotrexate in systemic lupus erythematosus
20. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease - A review of 36 patients
21. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease)
22. Methotrexate use in systemic lupus erythematosus
23. Methotrexate - Cautions; side effects
24. Maintenance azathioprine reduces the incidence of relapse in systemic lupus erythematosus (SLE)
25. Cytotoxic drugs
26. Prednisolone and azathioprine compared to prednisone plus low dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis
27. Azathioprine: Side effects
28. Mercaptopurine pharmacogenetics: Monogenetic inheritance of erythrocyte thiopurine methyltransferase deficiency
29. Azathioprine: Cautions
30. Cyclosporin in the treatment of lupus nephritis
31. The effects of cyclosporin in patients with systemic lupus
32. Cyclosporin plus steroids versus steroids alone in the treatment of lupus nephritis
33. Use of cyclosporin in lupus nephritis
34. Cyclosporin A in the treatment of systemic lupus erythematosus: Results of an open clinical study
35. Long-term treatment of systemic lupus erythematosus with cyclosporin A
36. An audit of cyclosporin for SLE and related overlap syndromes: Limitations of use
37. The place of cyclosporine A in the treatment of connective tissue diseases
38. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus
39. The treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus - A report of three cases
40. Cytotoxic drugs
41. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients
42. Chlorambucil therapy in rheumatoid arthritis: Clinical experience in 28 patients and literature review
43. The oncogenicity of chlorambucil in rheumatoid arthritis
44. Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses
45. Mycophenolate mofetil for severe autoimmune haemolytic anaemia
46. Treatment of pemphigus vulgaris with mycophenolate mofetil
47. Bullous pemphigoid treated with mycophenolate mofetil
48. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy
49. Mycophenolate mofetil in lupus nephritis
50. Additive immunosuppressive effect of combined mycophenolate mofetil and cyclosporin A in experimental rat cardiac transplantation
51. Mycophenolate mofetil: Side effects
52. Cladribine in the treatment of systemic lupus erythematosus nephritis
53. A pilot study of 2-chloro-2′deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis
54. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study
55. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: Report of 2 cases
56. Intravenous immunoglobulins for inducing remissions in systemic lupus erythematosus
57. Is there a future for extracorporeal photochemotherapy in the treatment of the rheumatologic diseases?
58. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration
59. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma
60. Blast crisis of chronic myelogenous leukaemia in long-lasting systemic lupus erythematosus: Regression of both diseases after autologous bone marrow transplantation
61. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation
62. Haematopoietic stem-cell transplantation for systemic lupus erythematosus
63. The potential role of autologous stem cell transplantation in patients with systemic lupus erythematosus
64. Clinical and management aspects of the antiphospholipid syndrome
65. The antiphospholipid syndrome: Ten years on
66. Which patients with antiphospholipid antibodies should be treated and how?
67. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients
68. Antiphospholipid antibodies in autoimmune and infectious diseases. Participation of beta-2-glycoprotein 1
69. Fetal outcome of lupus pregnancy: A retrospective case-control study of the Hopkin's lupus cohort
70. The mother in systemic lupus erythematosus